Post-traumatic Stress and Depressive Symptoms in Women With Ovarian Cancer 3-6 Months After Diagnosis.

Ovarian cancer PTSD chemotherapy functioning surgery trauma

Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Feb 2024
Historique:
received: 13 12 2023
revised: 29 12 2023
accepted: 02 01 2024
medline: 3 2 2024
pubmed: 3 2 2024
entrez: 2 2 2024
Statut: ppublish

Résumé

The potentially traumatic role of severe life-threatening medical conditions is still debated in psychiatry and not yet recognized, particularly among post-traumatic stress disorders. However, increasing evidence suggests the psychopathological impact of severe medical conditions related to their poor prognosis, high lethality, treatments heaviness and invasiveness. Ovarian cancer (OC) is one of the malignancies with the highest mortality and the aim of this study was to investigate post-traumatic stress and depressive symptoms in women 3 to 6 months after diagnosis. A sample of 83 women diagnosed with OC at different stages (from AI to IV) was recruited and assessed by means of the: Structural Clinical Interview for Mental Disorders according to DSM-5 (SCID-5), Trauma and Loss Spectrum Self-Report (TALS-SR), Impact Event Scale-Revised (IES-R), Hamilton Rating Scale for Depression (HAM-D), Mood Spectrum-Self Report (MOOD-SR), Work and Social Adjustment Scale (WSAS). Full data on the psychiatric assessments were available for 45 patients: 13 (28.9%) patients reported a diagnosis of PTSD. Patients with PTSD reported statistically significant higher depressive symptoms and more severe impact on work and social functioning compared to those without PTSD. Our results highlight the need to carefully assess the potentially traumatic burden of a diagnosis of OC and its association with depressive symptoms for their impact on patients' global functioning, in order to provide appropriate preventive and therapeutic interventions.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
The potentially traumatic role of severe life-threatening medical conditions is still debated in psychiatry and not yet recognized, particularly among post-traumatic stress disorders. However, increasing evidence suggests the psychopathological impact of severe medical conditions related to their poor prognosis, high lethality, treatments heaviness and invasiveness. Ovarian cancer (OC) is one of the malignancies with the highest mortality and the aim of this study was to investigate post-traumatic stress and depressive symptoms in women 3 to 6 months after diagnosis.
PATIENTS AND METHODS METHODS
A sample of 83 women diagnosed with OC at different stages (from AI to IV) was recruited and assessed by means of the: Structural Clinical Interview for Mental Disorders according to DSM-5 (SCID-5), Trauma and Loss Spectrum Self-Report (TALS-SR), Impact Event Scale-Revised (IES-R), Hamilton Rating Scale for Depression (HAM-D), Mood Spectrum-Self Report (MOOD-SR), Work and Social Adjustment Scale (WSAS).
RESULTS RESULTS
Full data on the psychiatric assessments were available for 45 patients: 13 (28.9%) patients reported a diagnosis of PTSD. Patients with PTSD reported statistically significant higher depressive symptoms and more severe impact on work and social functioning compared to those without PTSD.
CONCLUSION CONCLUSIONS
Our results highlight the need to carefully assess the potentially traumatic burden of a diagnosis of OC and its association with depressive symptoms for their impact on patients' global functioning, in order to provide appropriate preventive and therapeutic interventions.

Identifiants

pubmed: 38307582
pii: 44/2/829
doi: 10.21873/anticanres.16875
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

829-838

Informations de copyright

Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Claudia Carmassi (C)

Division of Psychiatry, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; claudia.carmassi@unipi.it.

Virginia Pedrinelli (V)

Division of Psychiatry, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Sara Fantasia (S)

Division of Psychiatry, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Debora Andreoli (D)

Division of Psychiatry, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Federico Giovannoni (F)

Division of Psychiatry, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Enrico Massimetti (E)

Division of Psychiatry, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Stefania Cosio (S)

Division of Gynecology and Obstetrics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Liliana Dell'osso (L)

Division of Psychiatry, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Angiolo Gadducci (A)

Division of Gynecology and Obstetrics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Classifications MeSH